Teva Pharmaceutical Appoints New Member to Leadership Team
Teva Pharmaceutical Ind. ltd. appointed Dr. Eric Hughes as Executive Vice President, Global R&D and Chief Medical Officer, effective August 1. Hughes will be based at Teva’s US headquarters in Parsippany, the company announced on July 1.
Bringing nearly 20 years of drug development experience to the role, Hughes was most recently senior vice president of clinical development and translational medicine at Vertex Pharmaceuticals, according to Teva. He also led the global development unit Immunology, Hepatology and Dermatology at Novartis.
Hughes began his career in the pharmaceutical industry in 2004 at the start of clinical research at Bristol Myers-Squibb Co. and then at the Schering-Plough Research Institute. He worked for Merck Research Laboratories for a year before returning to Bristol Myers-Squibb in 2010 where he was eventually promoted to head of virology, fibrotic diseases, genetically defined diseases, autoimmunity and exploratory and translational clinical research in cardiology.
Hughes, who has co-authored more than 30 articles in peer-reviewed scientific journals, received his MD and Ph.D. from Yale School of Medicine.
“As an accomplished scientist with a specialized training in infectious diseases and immunology, combined with his track record of leading clinical development activities and talent in multiple therapeutic areas around the world, I believe Eric has the experience and expertise to lead our global R&D function and execute on the company-wide vision of innovation and growth,” said Kåre Schultz, President and CEO of Teva, in a statement.
Schultz also thanked Hafrun Fridriksdottir, the outgoing executive vice president, “for more than 25 years of service to Teva and its legacy companies” and wished her luck in her “next adventure.”